Revmond (Revmonn)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceEfenafetatEfenafetat
Similar drugsTo uncover
  • Revmond
    spray externally 
    Honey Manufacuring GmbH     Germany
  • Revmond
    gel externally 
    Honey Manufacuring GmbH     Germany
  • Revmond
    emulsion externally 
    Honey Manufacuring GmbH     Germany
  • Revmond
    cream externally 
    Honey Manufacuring GmbH     Germany
    • Dosage form: & nbsp

    Spray for local and external use.

    Composition:

    Active substance:

    Etophenamate 100.0 mg

    Excipients:

    Diisopropyl adipate 100.0 mg; cetomacrogol oleate 60.0 mg; macrogol-400 30.0 mg; isopropanol 385.0 mg; propylene glycol 40.0 mg; purified water 222.5 mg.

    Description:Transparent, colorless or slightly yellowish solution, with a characteristic odor of isopropanol.
    Pharmacotherapeutic group:Non-steroidal anti-inflammatory drug (NSAID)
    ATX: & nbsp

    M.02.A.A.06   Efenafetat

    Pharmacodynamics:

    Rheumont spray for external use contains 10% (by weight) of etofenamate, which has pronounced anti-inflammatory and analgesic properties.

    Etophenamate is a non-steroidal anti-inflammatory drug whose action is based, on the fact that it indiscriminately suppresses cyclooxygenase 1 and 2 types, disrupts the metabolism of arachidonic acid. As a result, the synthesis of prostaglandins is inhibited and the formation of inflammatory mediators is reduced.

    Pharmacokinetics:

    Etophenamate is lipophilic in nature, which causes its good penetration through the skin. Concerning etofenamate is used mainly in preparations intended for external use.

    Etophenamate penetrates through the skin and is distributed into affected tissue, in which it reaches therapeutic concentrations. The distribution of ethofenamate is characterized by accumulation in inflamed tissue, where the implementation of therapeutic action is necessary. Maximum concentrations of ethofenamate in plasma are achieved after a single application of Rheumont Spray after 12-24 hours after application. The relative bioavailability of the drug does not exceed 20%. Efenafetat is excreted by the kidneys and through intestines in the form of its metabolites and their compounds.
    Indications:

    Rheumont spray for external use is prescribed in the following cases: scovered injuries and bruises, sports injuries, injuries of soft tissues and joints, aboutstoarthrosis, periarthritis of the shoulder joint, epicondylitis, lumbago, ankylosing spondylitis, tendonitis, tenosynovitis, and peritendinitis.

    Contraindications:

    Individual hypersensitivity to one of the components of the drug,to acetylsalicylic acid or other NSAIDs, anamnestic data on an attack of bronchial obstruction, rhinitis; urticaria after taking acetylsalicylic acid or other non-steroidal; anti-inflammatory drug, violation of the integrity of the skin.

    Rheumont Spray for external use is not recommended for use in children's practice, because of the lack of clinical safety data.

    Carefully:

    Erosive-ulcerative lesions of the gastrointestinal tract, severe violations of liver and kidney function, chronic heart failure, elderly age, bronchial asthma.

    Pregnancy and lactation:

    Rheumont Spray for external use is contraindicated for use during pregnancy, since it is established that etofenamate penetrates the placental barrier.

    In the period of application of the drug Revmont spray for external use, nursing mothers should refuse breastfeeding.

    Dosing and Administration:

    Rheumont spray for topical use is prescribed topically, applied directly to diseased areas, spreading as far as possible over a larger area.It is recommended to rub the solution thoroughly with circular motions after every 1-2 strokes, until it dries completely on the skin. Typically, with one application, up to 7 pressures are produced.

    The dose of the drug, released by a single press, contains 18 mg of etofenamate.

    The spray is applied 3-5 times a day. If necessary, the dose should be increased. After applying the product, you should thoroughly wash your hands.

    The maximum duration of the drug without a doctor's consultation is 14 days.

    The course of treatment is from 1-2 weeks to several months after consulting a doctor.

    Side effects:

    In rare cases, reversible allergic reactions in the form of urticaria, dermatitis, peeling, erythema, or itching may develop in the area of ​​application of the Rheumont spray for external use. In this case, stop using the drug and consult a doctor.

    Overdose:

    Information on cases of overdose Rheumont Spray for external use are absent.

    With accidental ingestion, it is possible to develop systemic adverse reactions; treatment: gastric lavage, induction of vomiting, Activated carbon, forced diuresis, symptomatic therapy; Dialysis is not effective due to the high degree of binding to the proteins of ethofenamate (about 99%).

    Interaction:

    Interaction Rheumont Spray for external use with other medications has not been established.

    Special instructions:

    Rheumont Spray for external use should not be used if there is individual hypersensitivity to etofenamate, the products of its metabolism or individual auxiliary components in the formulation.

    Effect on the ability to drive transp. cf. and fur:

    Rheumont Spray for external use does not affect the ability to drive vehicles and work with complex mechanisms.

    Form release / dosage:

    Spray for external use 10%.

    Packaging:

    For 50 ml spray for external use in a glass bottle of brown with a screw-on dispenser dispenser. The bottle together with the instruction for use is placed in a cardboard box.

    Storage conditions:

    At a temperature not exceeding 25 °C. Store in a place inaccessible to children.

    Shelf life:3 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:LP-001385
    Date of registration:20.12.2011
    The owner of the registration certificate:Honey Manufacuring GmbHHoney Manufacuring GmbH Germany
    Manufacturer: & nbsp
    Representation: & nbspMEDA PHARMA LLCMEDA PHARMA LLC
    Information update date: & nbsp16.09.2015
    Illustrated instructions
      Instructions
      Up